Marketing Authorisations
|
|
|
|
|
Informing patients does not necessarily imply lower participation
|
|
|
|
|
|
|
|
|
|
In triple-drug combination: virological advantage in chronic hepatitis C
|
|
|
|
|
|
|
|
|
|
After boceprevir, if necessary
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Yet another reason to avoid bupropion
|
|
|
|
|
|
|
|
|
|
Patients should be informed
|
|
|
|
|
|
|
|
|
|
Already available in 4 countries
|
|
|
|
|
|
|
|
|
|
Pharmacovigilance confirms adverse signals noticed prior to market release
|
|
|
|
Reviews
|
|
|
|
|
Urgently assess the risk of infection and treat for 28 days if necessary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|